Results in line with our expectations.
Executive Vice President Finance
The results for the 2018/2019 financial year are in line with our expectations. Servier delivered a strong performance with an 11.1% growth in revenue at constant exchange rates. Business was driven by good results in oncology, particularly in the United States, strong growth in brand-name medicines in China, Russia and Brazil, and a dynamic generic activity. We also successfully completed an inaugural U.S. private placement (USPP) of $405 million. This placement enables us to diversify our sources of funding and extend our average debt maturity. It is a testament to the confidence that investors place in us. Finally, EBITDA is on the rise and is higher than our forecasts. Thus, the financial health of the Group at the end of this fiscal year enables us to pursue the implementation of our strategic plan as it has been defined.